口服普萘洛尔个体化给药治疗婴儿血管瘤的前瞻性研究。
Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study.
作者信息
Prasad Arun, Sinha Amit Kumar, Kumar Bindey, Prasad Abhiranjan, Kumari Manju
机构信息
Department of Pediatrics, All India Institute of Medical Sciences, Patna, India.
Department of Pediatric Surgery, All India Institute of Medical Sciences, Patna, India.
出版信息
Pan Afr Med J. 2019 Apr 8;32:155. doi: 10.11604/pamj.2019.32.155.16760. eCollection 2019.
INTRODUCTION
infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to find out the appropriate dosage of oral propranolol for treatment of infantile hemangioma.
METHODS
A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day.
RESULTS
17/22(76%) patients showed regression of the tumor at the dose of 1- 1.5 mg/kg/d. 5/22(24%) patients were unresponsive to the treatment with the lower dose and they did not respond even with the gradually escalated dose of 3-4 mg/kg/day.
CONCLUSION
Propranolol in a lower dose of 1-1.5 mg/kg/day is safe and efficacious in the treatment of infantile hemangioma and the lesions which do not show initial response to the lower dose are unlikely to respond to the higher dose of 3-4 mg/kg/day.
引言
婴儿血管瘤是婴儿期最常见的良性肿瘤。目前，口服普萘洛尔是治疗婴儿血管瘤的首选药物，但对于该病症的推荐剂量尚无共识。因此开展本研究以确定治疗婴儿血管瘤的口服普萘洛尔合适剂量。
方法
对25例婴儿血管瘤患者进行前瞻性研究，从较低剂量1毫克/千克/天开始，逐渐增加普萘洛尔剂量进行治疗。
结果
17/22（76%）的患者在剂量为1 - 1.5毫克/千克/天时肿瘤出现消退。5/22（24%）的患者对较低剂量治疗无反应，即使剂量逐渐增加至3 - 4毫克/千克/天也无反应。
结论
1 - 1.5毫克/千克/天的较低剂量普萘洛尔治疗婴儿血管瘤安全有效，对较低剂量初始无反应的病灶不太可能对3 - 4毫克/千克/天的较高剂量产生反应。
Zotero 插件